Form 6-K Altamira Therapeutics For: Jan 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Altamira Therapeutics (CYTO) Enters ATM Agreement
January 19, 2024 4:47 PM ESTOn January 19, 2024, Altamira Therapeutics (NASDAQ: CYTO) entered into an At the Market Offering Agreement (the Agreement) with H.C. Wainwright & Co., LLC (HCW), as sales agent or principal, relating to the offer and sale of the Companys common shares, par value $0.002 per share, from time to time, having an aggregate offering amount of up to $1.66 million (the Offering). On January 19, 2024, pursuant to the Agreement, the Company filed a prospectus supplement (the Prospectus Supplement), including an accompanying base prospectus, dated December 8, 2021, forming a part of its effective registration statement on Form F-3 (File No. 333-261127),... More
